Bayer’s dual neurokinin 1 and 3 receptor antagonist elinzanetant (Lynkuet) reduced the frequency and severity of menopausal vasomotor symptoms in phase 3 OASIS trials, providing a once daily, nonhormonal treatment option for moderate to severe hot flashes.
Maternal age distribution shifts dramatically as overall birth rates continue a 30-year decline, with women younger than 30 now accounting for less than half of all births, and an increase of older mothers.
FDA approves gepotidacin, a first-in-class oral antibiotic, for treating uncomplicated urinary tract infections in females aged 12 and older, based on phase III trial results.
Steven J. Fleischman, MD, MBA, FACOG, president of the American College of Obstetricians and Gynecologists released remarks on analgesic safety for patients who are pregnant.
CDC reports nearly 2% decrease in STIs in the U.S. in 2023, providing hope for slowing the epidemic and addressing disparities in affected communities.